Changes in Hong Kong stocks | Maike Pharmaceutical-B (02335) rose nearly 6% and has received the first funding for the “Major New Drug Creation” project under the National Science and Technology Project

The Zhitong Finance App learned that McPharmaceutical-B (02335) rose nearly 6% at the end of the session. As of press release, it had risen 3.83% to HK$16.53, with a turnover of HK$546.78 million.

According to the news, on November 4, Maike Pharmaceutical-B issued an announcement. The company and Beijing Tiantan Hospital (Beijing Tiantan Hospital) affiliated to Capital Medical University jointly undertook a research project involving the company's key product MT200605 under the “Major New Drug Creation” national science and technology project, and has recently received the first special funding from the central financial administration for this project. The company has also obtained ethical approval from the MT200605 phase III clinical trial team leader unit. This course is entitled “Major New Drug Creation” (this topic) under the National Science and Technology Major Project, and is jointly undertaken by the Company and Beijing Tiantan Hospital.

The board of directors believes that this cooperation and the receipt of the first special fund are of strategic significance to the Group. Based on the positive results achieved in the MT200605 phase II clinical trial, this cooperation will give full play to the professional advantages of Beijing Tiantan Hospital in stroke research and multi-center clinical trials to support the subsequent clinical development of MT200605. At the same time, project funding will provide additional financial support for related R&D activities to help the continuous advancement of product clinical research and development work. After the completion of the MT200605 phase II clinical trial, the company has received the first special funding from the central government for this project and is promoting clinical development of MT200605 to phase III.